

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): CHOO et al.

Appln. No.: 09

646,353

Series Code ↑

Serial No. ↑

Filed: November 18, 2000

Hon. Commissioner of Patents  
Washington, D.C. 20231.

Group Art Unit

Examiner: unki

Atty. Dkt. P 273

MM

Appln. Title: NUCLEIC

Sir:

**REPLY/AMENDMENT/LETTER**

Date: April 12,

This is a reply/amendment/letter in the above-identified application and includes the herewith attach which is incorporated hereinto by reference and the signature below is treated as the signature to the signature thereto.

**FEE REQUIREMENTS FOR CLAIMS AS AMENDED**

## 1. Small Entity claim

- A. ☐ NOT made  
B. ☐ Withdrawn  
C. ☐ made herewith  
D. ☒ made previously

For B & C  
See **Required**  
**Separate Paper**  
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small
----------------------------------	------------------------------------	---------------	-------------

2. Total Effective Claims	49	**minus	29	20	x \$18/\$9		
3. Independent Claims	4	***minus	4	0	x \$84/\$42		
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... add					+ \$280/\$140 =	+ \$0	104/204
5. Original due Date: April 12, 2002		<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)	\$110/\$55 =			115/215	
		(2 mos)	\$400/\$200 =	+ \$0		116/216	
		(3 mos)	\$920/\$460 =			117/217	
		(Usable only for ≤ 2mo.OA --- 4 mos)	\$1,440/\$720=			118/218	
		(Usable only for 30 day/1mo.OA --- 5 mos)	\$1,960/\$980=			128/228	
7. Enter any previous extension fee paid since above original due date and subtract					- \$0		
8. Extension Fee Attached					+ \$0		
9. If Terminal Disclaimer attached, add Rule 20(d) official fee .....					+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c), .....					+ \$180	+ \$0	126
or if Rule 97(d) Request .....					+ \$180	+ \$0	126
11. After-Final Request Fee per rules 129(a) and 17(r) .....					+ \$740/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b) .....					x \$740/370 ea	+ \$0	149/249
13. Request for Continued Examination (RCE) .....					+ \$740/370	+ \$0	1179/1279
14. Petition fee for .....					+ \$0		
15. TOTAL FEE ENCLOSED =					\$180		

16. \*If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. \*\*If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. \*\*\*If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

Our Deposit Account No. 03-3975)

(Our Order No. 071278

C#

273884

MM

**CHARGE STATEMENT:** The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT **does not authorize** charge of the **issue fee** until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP

Intellectual Property Group

By Atty: Blair E. Taylor


Reg. No. 44370

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Sig:



Fax:

(703) 905-2500

Tel:


(703) 905-2198

Att/Sec: RFT/nlh

Application No.: 09/646,353

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: This applicant has not fully complied with sequence listing rules, which requires the use of SEQ ID NO: See for e.g. page 46 (claim 20) and page 10 of the specification, do not comply with the sequence rules, as required by 37 CFR 1.82(d)

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**RECEIVED**  
APR 16 2002  
TECH CENTER 1600/2900

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**